And more importantly, diagnosis of AFP-negative HCC is meanful for clinical practice because the prognosis of these patients is poor than that of AFP-positive patients for poorly differentiated and rapid malignant progression (8–10),therefor, the clinical diagnosis of AFP-negative HCC has become an urgent issue hindering the early treatment and improved prognosis of HCC in general, so we urgently need to find new serum biomarkers other than AFP to facilitate early screening and the early diagnosis of AFP-negative HCC (11). This evidence concerns the gene AFP and hepatocellular carcinoma.